1,044
Participants
Start Date
February 28, 2005
Primary Completion Date
February 28, 2011
Study Completion Date
February 28, 2011
Cisplatin
80mg/m2 iv on day 1 of each 3 week cycle, for a maximum of 6 cycles
Gemcitabine
1250mg/m2 on days 1 and 8 of each 3 week cycle for a maximum of 6 cycles
Placebo
iv on day 1 of each 3 week cycle until disease progression
bevacizumab [Avastin]
15mg/kg 1v on day 1 of each 3 week cycle until disease progression
bevacizumab [Avastin]
7.5 mg/kg iv on day 1 of each 3 week cycle until disease progression
Taipei
Kueishan
Taichung
Taichung
Hong Kong
Brussels
Sofia
Budapest
Sofia
Santa Fe
Sydney
Sydney
Wollongong
Canberra
Leuven
Parkville
Melbourne
San Miguel de Tucumán
Liège
Plovdiv
Brisbane
Tugun
Nyíregyháza
Veliko Tarnovo
Adelaide
Kurralta Park
Adelaide
Mendoza
Perth
Haine-Saint-Paul
Mosdós
Bahía Blanca
Stara Zagora
Székesfehérvár
Zalaegerszeg
Varna
Szombathely
Candiolo
Bangkok
Athens
Athens
Marseille
Caen
Berlin
Genova
Girona
Rozzano
Milan
Milan
Hamburg
Hamburg
Hamburg
Montbéliard
Madrid
Madrid
Madrid
Madrid
Málaga
Montpellier
Rennes
Göttingen
San Cristóbal de La Laguna
Seville
Seville
Valencia
Reggio Emilia
Parma
Kfar Saba
Saint-Herblain
Essen
Valencia
Valencia
Valencia
Barakaldo
Petah Tikva
Chiang Mai
Leverkusen
Ramat Gan
Vandœuvre-lès-Nancy
Mainz
Thessaloniki
Hemer
Strasbourg
Alexandroupoli
Mannheim
Lyon
Heidelberg
Pierre-Bénite
Rouen
Karlsruhe
Napoli
München
Gauting
Belfort
Jerusalem
Bobigny
Catania
Moscow
Moscow
Moscow
Moscow
Moscow
Balashikha
Saint Petersburg
Saint Petersburg
Saint Petersburg
Tel Aviv
Belo Horizonte
Buenos Aires
Buenos Aires
Santa Fe
Porto Alegre
Rio de Janeiro
São Paulo
Calgary
Edmonton
Victoria
Moncton
London
Mississauga
Newmarket
Toronto
Toronto
Toronto
Greenfield Park
Montreal
Montreal
Sainte-Foy
Ostrava
Ostrava
Prague
Ústí nad Labem
Hong Kong
Taipei
Perugia
Roma
Roma
Gdansk
Gdynia
Lublin
Olsztyn
Poznan
Szczecin
Warsaw
Alicante
Barcelona
Barcelona
Barcelona
Guildford
London
Manchester
Sheffield
Sutton
Yeovil
Hoffmann-La Roche
INDUSTRY